Your browser doesn't support javascript.
loading
NLRC5 Might Promote Endometrial Cancer Progression by Inducing PD-L1 Expression.
Zhu, Su-Ding; Zhang, Jing; Liu, Xiao-Jing; Zhang, Jun-Hui; Wei, Bing; Wang, Wen-Yan; Fan, Yi-Jun; Li, Dan; Cao, Yun-Xia; Zhan, Lei.
Affiliation
  • Zhu SD; 533251The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, People's Republic of China.
  • Zhang J; 533251The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, People's Republic of China.
  • Liu XJ; 533251The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, People's Republic of China.
  • Zhang JH; 36639The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, People's Republic of China.
  • Wei B; 533251The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, People's Republic of China.
  • Wang WY; 533251The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, People's Republic of China.
  • Fan YJ; 533251The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, People's Republic of China.
  • Li D; 533251The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, People's Republic of China.
  • Cao YX; 36639The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, People's Republic of China.
  • Zhan L; 533251The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, People's Republic of China.
Technol Cancer Res Treat ; 21: 15330338221112742, 2022.
Article in En | MEDLINE | ID: mdl-35880269
ABSTRACT

Aims:

The NOD-like receptor (NLR) family, caspase recruitment (CARD) domain containing 5 (NLRC5) was dysregulated in endometrial cancer (EC). However, the potential regulatory mechanisms of NLRC5 in EC remained unclear. We aimed to explore whether NLRC5 could regulate the programmed cell death protein ligand 1 (PD-L1) in EC. We also investigated the related molecular which led to the inactivation of NLRC5 in EC.

Methods:

The expressions of NLRC5 and PD-L1 in endometrium tissue microarray were detected by immunohistochemistry. Pearson's correlation analysis was performed to detect the expression correlation between NLRC5 and PD-L1. Immunofluorescence staining, western blotting, and quantitative real-time PCR (qRT-PCR) were used to detect the role of NLRC5 in PD-L1 in EC cell lines. The somatic mutation in EC patients was detected by whole-exome sequencing (WGS).

Results:

NLRC5 was downregulated in the endometrium of EC patients when compared to those in the normal endometrium. The level of PD-L1 in the endometrium of EC patients was higher when compared to those in the normal endometrium. There was a negative expression correlation between NLRC5 and PD-L1. NLRC5 could promote the expression of PD-L1 in EC cell lines. The mutations of ANKRD20A2, C2orf42, ADGRB3, AVPR2, GOLGA6C, and IPPK may lead to the downregulation of NLRC5 in EC patients.

Conclusion:

NLRC5 could inhibit the activation of PD-L1 in EC. Mutations of ANKRD20A2, C2orf42, ADGRB3, AVPR2, GOLGA6C, and IPPK may lead to the downregulation of NLRC5 in EC patients. Future study should investigate the mechanism of NLRC5 in PD-L1, as well as the mechanism of ANKRD20A2, C2orf42, ADGRB3, AVPR2, GOLGA6C, and IPPK in NLRC5.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Endometrial Neoplasms / B7-H1 Antigen Limits: Female / Humans Language: En Journal: Technol Cancer Res Treat Journal subject: NEOPLASIAS / TERAPEUTICA Year: 2022 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Endometrial Neoplasms / B7-H1 Antigen Limits: Female / Humans Language: En Journal: Technol Cancer Res Treat Journal subject: NEOPLASIAS / TERAPEUTICA Year: 2022 Document type: Article